Business Wire

MA-VERACODE

2.4.2024 09:31:35 CEST | Business Wire | Press release

Share
Advancing Cloud-Native Application Security: Veracode Connects Security from Code to Cloud with the Acquisition of Longbow Security

Veracode, a global leader in application risk management, today announced the acquisition of Longbow Security, a pioneer in security risk management for cloud-native environments. The acquisition marks the next exciting phase of Veracode, underscoring the company’s commitment to help organizations effectively manage and reduce application risk across the growing attack surface.

The integration of Longbow into Veracode enables security teams to discover cloud and application assets quickly and easily assess their threat exposure using automated issue investigation and root cause analysis. Longbow provides a centralized view of risk for cloud assets and applications, thereby simplifying complex workflows, enabling faster and more effective remediation, and improving overall security posture. The result is reduced risk and fewer vulnerabilities in applications and cloud infrastructures.

Increased adoption of cloud infrastructure, combined with developers taking on more responsibility for the creation, deployment, and security of software, has introduced operational complexity. Organizations now require a deeper understanding of their risk profile within changing environments and a continuous security feedback loop throughout the software development life cycle.

“Security teams are drowning in alerts that lack sufficient detail on the level of business risk, degree of exploitability of a flaw, and specific code-level insight to keep pace with remediation requirements. As a result, risk continues to accumulate,” said Brian Roche, Chief Product Officer at Veracode. “With the combination of Veracode and Longbow, teams can get a comprehensive view of their risk, automate prioritization of what matters most, and, with Veracode Fix, automate remediation of code security flaws.”

Longbow and Veracode Simplify Cloud Application Security for Overloaded Teams

With 71 percent of organizations shouldering the burden of “security debt” (flaws in applications that remain unfixed for one year), teams must act quickly to reduce their threat exposure. Yet, sufficient visibility and alert fatigue continue to plague cloud and application security professionals today. With Longbow, Veracode customers can address these challenges in four ways:

  • Unified visibility of risk across applications, code, and cloud. This gives teams insight to tackle significant issues that matter most to the business.
  • Orchestrated remediation from code to cloud, enabling teams to prioritize and remediate with Veracode’s AI-driven fix capabilities.
  • Actionable insights with ‘Best Next Action’ advice, so customers can conduct a root cause analysis and pinpoint the best path to remediation.
  • Continuous monitoring and assessment via real-time vulnerability discovery across application portfolios and runtime environments, meaning customers know exactly what is running and where.

Derek Maki, Co-Founder & Chief Product Officer at Longbow said, “We founded Longbow with a mission to simplify an increasingly complex application security risk management process and help organizations reduce risk at scale. By joining forces with Veracode, our combined solutions provide unmatched visibility, automation, and remediation capability for security and engineering teams. We are excited to take cloud-native application security to the next level.”

“This is the perfect fit for Longbow,” said Dayne Myers, Co-founder & Chief Executive Officer of Longbow. “After careful consideration, we believe that our technology and team align seamlessly with Veracode's vision, making this the best choice for Longbow’s future."

“We’re thrilled to welcome Longbow to Veracode and expand our platform capabilities with industry-leading application security posture management for today’s enterprise requirements,” closed Sam King, Chief Executive Officer at Veracode. “The integration of our solutions provides organizations with a holistic application risk management platform that spans code to cloud. Veracode combined with Longbow advances the field of application security and enables customers to secure their increasingly complex application landscape more efficiently.”

Longbow is available immediately. To learn more about the platform, visit the Longbow website. Read the blog for information on the acquisition.

About Veracode

Veracode is intelligent software security. The Veracode Software Security Platform continuously finds flaws and vulnerabilities at every stage of the modern software development lifecycle. Using powerful AI trained on a carefully curated, trusted dataset from experience analyzing trillions of lines of code, Veracode customers fix flaws faster with high accuracy. Trusted by security teams, developers, and business leaders from thousands of the world’s leading organizations, Veracode is the pioneer, continuing to redefine what intelligent software security means.

Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and Twitter.

Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240401671481/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release

Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye